2.55 USD
-0.02 (-0.78%)
2.52 USD
-0.03 (-1.18%)
Overall SPRO gets a fundamental rating of 4 out of 10. We evaluated SPRO against 530 industry peers in the Biotechnology industry. SPRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year SPRO has reported negative net income.
SPRO had a negative operating cash flow in the past year.
SPRO had negative earnings in 4 of the past 5 years.
In the past 5 years SPRO always reported negative operating cash flow.
1.2 Ratios
SPRO has a Return On Assets of -80.92%. This is in the lower half of the industry: SPRO underperforms 68.30% of its industry peers.
SPRO has a Return On Equity of -165.46%. This is in the lower half of the industry: SPRO underperforms 65.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.92% | ||
| ROE | -165.46% | ||
| ROIC | N/A |
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRO has been increased compared to 1 year ago.
The number of shares outstanding for SPRO has been increased compared to 5 years ago.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -10.47, we must say that SPRO is in the distress zone and has some risk of bankruptcy.
SPRO has a Altman-Z score of -10.47. This is in the lower half of the industry: SPRO underperforms 73.40% of its industry peers.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.47 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
SPRO has a Current Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.83, SPRO perfoms like the industry average, outperforming 46.04% of the companies in the same industry.
SPRO has a Quick Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
SPRO has a Quick ratio (3.83) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 |
3. Growth
3.1 Past
The earnings per share for SPRO have decreased strongly by -1228.57% in the last year.
Looking at the last year, SPRO shows a very negative growth in Revenue. The Revenue has decreased by -61.91% in the last year.
SPRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.46% yearly.
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
3.2 Future
SPRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.25% yearly.
The Revenue is expected to grow by 20.52% on average over the next years. This is a very strong growth
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SPRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SPRO is valuated cheaply with a Price/Forward Earnings ratio of 3.73.
SPRO's Price/Forward Earnings ratio is rather cheap when compared to the industry. SPRO is cheaper than 99.62% of the companies in the same industry.
SPRO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.73 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SPRO's earnings are expected to grow with 13.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.31%
EPS Next 3Y13.29%
5. Dividend
5.1 Amount
SPRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.55
-0.02 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.1%
Inst Owner Change0%
Ins Owners2.43%
Ins Owner Change-0.73%
Market Cap143.67M
Revenue(TTM)40.55M
Net Income(TTM)-43.84M
Analysts45.71
Price Target4.08 (60%)
Short Float %2.43%
Short Ratio1.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.64%
Min EPS beat(2)49.02%
Max EPS beat(2)92.26%
EPS beat(4)3
Avg EPS beat(4)44.13%
Min EPS beat(4)-20.18%
Max EPS beat(4)92.26%
EPS beat(8)6
Avg EPS beat(8)100.4%
EPS beat(12)10
Avg EPS beat(12)186.6%
EPS beat(16)11
Avg EPS beat(16)138.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)74.36%
EPS NY rev (3m)87.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.73 | ||
| P/S | 3.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.42 | ||
| P/tB | 5.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.79
EYN/A
EPS(NY)0.68
Fwd EY26.8%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.72
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.92% | ||
| ROE | -165.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 | ||
| Altman-Z | -10.47 |
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%
EBIT growth 1Y-3984.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-195.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-195.49%
OCF growth 3YN/A
OCF growth 5YN/A
SPERO THERAPEUTICS INC / SPRO FAQ
What is the ChartMill fundamental rating of SPERO THERAPEUTICS INC (SPRO) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SPRO.
Can you provide the valuation status for SPERO THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to SPERO THERAPEUTICS INC (SPRO). This can be considered as Fairly Valued.
What is the profitability of SPRO stock?
SPERO THERAPEUTICS INC (SPRO) has a profitability rating of 0 / 10.
What is the financial health of SPERO THERAPEUTICS INC (SPRO) stock?
The financial health rating of SPERO THERAPEUTICS INC (SPRO) is 6 / 10.